BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 21, 2018--
Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company
focused on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced that Antony Mattessich, President and Chief Executive Officer
of Ocular Therapeutix, will present at the 30th Annual Piper Jaffray
Healthcare Conference on Wednesday, November 28, 2018 at 3:00 PM ET at
the Lotte New York Palace Hotel in New York, NY.
In addition to the presentation, the management team will host investor
meetings at the conference. Investors attending the conference who are
interested in meeting with Ocular Therapeutix management should contact
their Piper Jaffray representative.
A live webcast of the presentation can be accessed by visiting the
Investors section of the Company’s website at investors.ocutx.com.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
formulation, development, and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary
bioresorbable hydrogel-based formulation technology. Ocular
Therapeutix’s lead product candidate, DEXTENZA® (dexamethasone insert),
has completed Phase 3 clinical development for the treatment of ocular
pain and inflammation following ophthalmic surgery. OTX-TP (travoprost
insert) is an intracanalicular insert in Phase 3 clinical development
for the reduction of intraocular pressure in patients with primary
open-angle glaucoma and ocular hypertension. The Company’s earlier stage
assets include OTX-TIC, an extended-delivery travoprost intracameral
implant for the reduction of intraocular pressure in patients with
glaucoma and ocular hypertension, as well as sustained release
intravitreal implants for the treatment of retinal diseases. These
intravitreal implants include the development of OTX-TKI, a tyrosine
kinase inhibitor (TKI), and, in collaboration with Regeneron, OTX-IVT,
an extended-delivery protein-based anti-vascular endothelial growth
factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant,
is FDA-approved to seal corneal incisions following cataract surgery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181121005067/en/
Source: Ocular Therapeutix, Inc.
Chris Brinzey, 339-970-2843